Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Louisiana Cuts Rates For Medicaid Providers
"Louisiana will start paying less money Tuesday to many private health care providers for taking care of Medicaid patients, a move the state health department estimates will save $86 million this year," The Associated Press/The Advocate reports. Adults in the program may also have to pay a small co-pay if they visit emergency rooms for non-emergency care. "The cuts come as the health department shrinks its spending to $7.9 billion in the new fiscal year that began July 1, down $240 million from last year. Nearly all the cuts will be levied on the Medicaid program for the poor, elderly and disabled. But Jerry Phillips, state Medicaid director, said the department believes it can cover nearly two-thirds of that gap through efficiencies and the continuation of other cuts made during the last budget year."
generic viagra online
Research Shows Temptation More Powerful Than Individuals Realize
Whether it"s highlighted in major news headlines about Argentinean affairs and Ponzi schemes, or in personal battles with obesity and drug addiction, individuals regularly succumb to greed, lust and self-destructive behaviors. New research from the Kellogg School of Management examines why this is the case, and demonstrates that individuals believe they have more restraint than they actually possess - ultimately leading to poor decision-making.
News of the day
New Survey Shows That Welsh Patients Are Happy With Their GPs
The results of the first Welsh GP patient survey have been published recently.
Diagnostics

Pharmalucence, Inc. Announces FDA Approval For Its Generic Sestamibi Kit

Pharmalucence, Inc., a leading supplier of radiopharmaceutical products, announced that it received approval from the U. S. Food and Drug Administration (FDA) Office of Generic Drugs for its Abbreviated New Drug Application (ANDA) to manufacture and market its Kit for the Preparation of Technetium Tc-99m Sestamibi Injection. The FDA has determined that Pharmalucence"s Sestamibi Kit is therapeutically equivalent to Cardiolite® 1, an imaging agent used in evaluating myocardial function and to detect coronary artery disease by localizing myocardial ischemia and infarction. The agent is also for use in breast imaging as a second line diagnostic after mammography to assist in the evaluation of breast lesions. Glenn Alto, President and CEO of Pharmalucence said, "When Pharmalucence was formed two years ago we committed to bring choice to the nuclear medicine community through an expanded line of radiopharmaceutical kits. The approval of our sestamibi kit marks the second generic imaging agent to emerge from the Pharmalucence Development team. Pharmalucence remains focused on delivering the products and enhancing the manufacturing assets that will provide nuclear medicine practitioners high quality imaging agents now and in the future." Pharmalucence will begin shipping their generic sestamibi kit on August 3. 1. Cardiolite® is a trademark of Lantheus Medical Imaging, Inc. Pharmalucence, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009